Keryx Biopharmaceuticals (KERX) Posts Q2 Loss of 5c/Share; Revs In-Line
Tweet Send to a FriendGet Alerts KERX Hot Sheet
Price: $7.94 -1.24%
EPS Growth %: +76.9%
Financial Fact:
Other research and development: 6.24M
Today's EPS Names:
BORN, EFUT, ZOOM, More
EPS Growth %: +76.9%
Financial Fact:
Other research and development: 6.24M
Today's EPS Names:
BORN, EFUT, ZOOM, More
Trade KERX Now!
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) reported Q2 EPS of ($0.05), $0.02 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $5 million versus the consensus estimate of $5 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Applied Materials, Inc. (AMAT) Tops Q2 EPS by 3c, Offers Guidance
- e-Future Information Technology, Inc. (EFUT) Widens Q1 Loss to RMB1.06/Share
- J.C. Penney Co., Inc. (JCP) Posts Q1 Loss of $1.31/Share; Comps Down 16.6%
Create E-mail Alert Related Categories
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
